The Lancet. Oncology. 2014 Oct 4. pii: S1470-2045(14)70211-6. doi: 10.1016/S1470-2045(14)70211-6. pmc: PMC4203149. mid: NIHMS632584 |
Prevention and early detection of prostate cancer. |
Cuzick J1, Thorat MA2, Andriole G3, Brawley OW4, Brown PH5, Culig Z6, Eeles RA7, Ford LG8, Hamdy FC9, Holmberg L10, Ilic D11, Key TJ12, La Vecchia C13, Lilja H14, Marberger M15, Meyskens FL16, Minasian LM17, Parker C18, Parnes HL19, Perner S20, Rittenhouse H21, Schalken J22, Schmid HP23, Schmitz-Dräger BJ24, Schröder FH25, Stenzl A26, Tombal B27, Wilt TJ28, Wolk A29 |
Abstract Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer. |
Copyright © 2014 Elsevier Ltd. All rights reserved. |
Publikations ID: 25281467 Quelle: öffnen |